CN108014098A - A kind of tolvaptan fast release micropill preparation, preparation method - Google Patents
A kind of tolvaptan fast release micropill preparation, preparation method Download PDFInfo
- Publication number
- CN108014098A CN108014098A CN201711272804.7A CN201711272804A CN108014098A CN 108014098 A CN108014098 A CN 108014098A CN 201711272804 A CN201711272804 A CN 201711272804A CN 108014098 A CN108014098 A CN 108014098A
- Authority
- CN
- China
- Prior art keywords
- tolvaptan
- preparation
- fast release
- release micropill
- capsule core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
Abstract
A kind of tolvaptan fast release micropill preparation, preparation method, it is related to drug preparation technique and application field, the fast release micropill preparation administering mode is oral administration, using blank capsule core as carrier, tolvaptan aqueous solution containing cosolvent and adhesive is upper drug solns, the tolvaptan dosage, according to weight ratio, tolvaptan dosage is the 0.0025%~0.3% of the capsule core；The oral dose of tolvaptan is not higher than 40 micrograms.The tolvaptan fast release micropill preparation has the features such as medicine-feeding rate is high, content uniformity is good, and drug release rapid-onset is fast.Meanwhile the fast release micropill preparation has the characteristics that Clinical practice compliance is good, safe.In addition, blank capsule core fluid bed medicine-feeding method is suitable for the preparation of extremely low specification tolvaptan drug oral preparation.
Description
Technical field
The present invention relates to drug preparation technique and application field, more particularly to a kind of tolvaptan fast release micropill preparation, system
Preparation Method and its application.
Background technology
Tolvaptan is to develop non-peptides selectivity antidiuretic hormone V2 receptor antagonists by Otsuka companies, 2009 5
Moon FDA approval tolvaptan piece（Tolvaptan, Samsca）Hyponatremia is treated, is uniquely to be approved to treat the oral type of the disease
Selective vasopressin antagonists.It is mainly used for comprehensive by congestive heart failure, hepatic sclerosis and antidiuretic hormone secretion deficiency to treat
Hyponatremia caused by simulator sickness.The multinomial randomized clinical control study for being used for CHF treatments for this product reported in recent years carries
Show, oral tolvaptan can raise Na ion concentration in blood plasma, help unnecessary moisture to be discharged from urine, can substantially mitigate trouble
Person's weight and oedema, and blood electrolyte balance is not destroyed.Tolvaptan better tolerance, is not necessarily limited the intake of water in treatment.With
Being approved for tolvaptan piece, a kind of doctor's new selections again more to treatment hyponatremia.【Products characteristics】Tolvaptan
It is uniquely to be approved to treat the oral type selectivity vasopressin antagonists of the disease, diuresis is strong, and without electrolyte excretion
Increase, available for treating various edema diseases, hyponatremia and patients with heart failure.Research is found, when Na ion concentration in blood plasma
During reduction, in order to keep the Na ion concentration of intraor extracellular to balance, extracellular liquid will enter into the cell, this like cell is just
Can swelling.When brain cell swelling, the symptom that may result in various hyponatremia occurs.Including dizzy, weak, headache, nausea, meaning
Know entanglement and consciousness decrement and faint from fear and occur.Serious hyponatremia can cause stupor and death, and tolvaptan piece exists at present
Also without corresponding research in the low blood sodium patient of severe.Tolvaptan piece can raise Na ion concentration in blood plasma, and it is unnecessary to help
Moisture is discharged from urine.In clinical studies, this product is compared with placebo, hence it is evident that the sodium ion increased in patients blood plasma is dense
Degree.The black surround warning of tolvaptan piece must take for patient in the hospital of the close monitoring of concentration of serum sodium.Because blood sodium is dense
Too fast serious Osmotic Demyelination Syndrome will be caused to occur if degree is elevated.Tolvaptan is developed by Otsuka companies
Non- peptides AVP2 receptor antagonists, it is only necessary to 1 times a day take orally.Multinomial the facing for CHF treatments for this product reported in recent years
Bed randomized control study is prompted, and oral tolvaptan can substantially mitigate weight in patients and oedema, and do not destroy blood electrolyte and put down
Weighing apparatus, and can effectively raise the concurrent low blood sodium of CHF patient.Tolvaptan better tolerance, is not necessarily limited the intake of water in treatment.Often
See adverse reaction for dry, thirsty sense, dizzy, nauseous, low blood pressure etc..The medicine lists in the U.S., and price is every（15mg）500
U.S. dollar.
The content of the invention
The purpose of the present invention one is the tolvaptan fast release micropill preparation for providing a kind of Orally-administrable.The mesh of the present invention
Two be to provide a kind of preparation method of tolvaptan fast release micropill preparation.
To achieve the above object, solution of the invention is：A kind of tolvaptan fast release micropill preparation is provided, it is described
Fast release micropill preparation administering mode is is administered orally, using blank capsule core as carrier, the tolvaptan water containing cosolvent and adhesive
Solution is upper drug solns, and the tolvaptan dosage, according to weight ratio, tolvaptan dosage is the 0.0025% of the capsule core
~0.3%；The oral dose of tolvaptan is not higher than 50 micrograms.
Further, the blank capsule core is sucrose capsule core or microcrystalline cellulose capsule core.
Further, one or more of the cosolvent in citric acid, acetic acid, hydrochloric acid, ascorbic acid.
Further, according to weight ratio, cosolvent dosage is the 20%~300% of tolvaptan.
Further, the adhesive be selected from hydroxypropyl methylcellulose (HPMC), povidone (PVP), syrup, starch slurry,
One or more in carmethose, gelatin, Arabic gum, methylcellulose.
Further, according to weight ratio, binder dosage is the 0.18%~1.68% of blank capsule core.
Further, any one described tolvaptan fast release micropill preparation further includes protective layer membrane material；The protection
One or more of the tunic material in acrylic resin, hydroxypropyl methylcellulose.
Further, the tolvaptan fast release micropill preparation, according to weight ratio, the dosage of protective layer membrane material is sky
The 1.0%~5.0% of white capsule core.
Further, the fast release micropill can be loaded on after capsule or addition proper auxiliary materials be pressed into after tablet take orally to
Medicine.
To achieve the above object, solution of the invention is：A kind of preparation of tolvaptan fast release micropill preparation is provided
Method, using blank capsule core as carrier, using the tolvaptan aqueous solution containing cosolvent and adhesive as upper drug solns, using fluid bed
Bottom sprays prescription method and prepares load medicine pellet, adds protective layer membrane material solution and obtains tolvaptan fast release micropill system through fluidized bed coating
Agent.
A kind of preparation method of tolvaptan fast release micropill preparation, including：
Step 1：The preparation of upper drug solns；
Step 2：Spray medicine in fluid bed bottom；
Step 3：Fluidized bed coating-protection film layer；
Step 4：After dry.
Further, the step 1 is specially to weigh tolvaptan by formula, and the citron acid solution for adding formula ratio is molten
Solution, is configured to quantitatively upper drug solns in the pure water solution for being then dissolved in including adhesive.
Further, the step 2 is specially and the blank capsule core of formula ratio is placed in fluid bed, starts fluid bed, to
The upper drug solns prepared in fluid bed in quantitative input step one.
Further, fluid bed medicine-feeding parameter is set by the process conditions of optimization during drug solns in the input, including
150~180m3h-1 of fan delivery, 2~7rmin-1 of feed flow revolution speed, 25~40 DEG C of temperature of charge, atomizing pressure
0.16MPa。
Further, the step 3 is specially to prepare 5% protective layer membrane material solution by formula ratio, and fluidized bed coating parameter is set
It is set to 150~180m3h-1 of fan delivery, feed flow 5~15rmin-1 of revolution speed, temperature of charge control is at 25~30 DEG C, mist
Change pressure 0.3MPa.Further, the step 4 is specially after the completion of being coated, to adjust fluid bed parameter, coating micro-pill is in 30
~40 DEG C of 15~45min of fluidized drying.
Embodiment
The above of the present invention is described in detail below in conjunction with specific embodiment, but this should not be interpreted as this hair
Bright technical solution is only limitted to following embodiments.
The formula of embodiment 11
| Tolvaptan | 80mg |
| Microcrystalline cellulose blank capsule core | 4000g |
| 0.3% acetum | 200ml |
| Hydroxypropyl methylcellulose (HPMC) | 300g |
| Talcum powder | 50g |
| Water | 5500g |
Preparation method：
(1) preparation of drug solns on：Tolvaptan 100mg is weighed by formula, adds 0.3% acetum 200mL dissolvings, then
It is dissolved in the aqueous solution for including hydroxypropyl methylcellulose (HPMC) 100g and is configured to drug solns on 1500g.
(2) medicine is sprayed at fluid bed bottom：Microcrystalline cellulose blank capsule core 4000g is placed in fluid bed, starts fluid bed, if
Put fluid bed medicine-feeding parameter:Fan delivery 150m3h-1, feed flow revolution speed 5rmin-1, temperature of charge control are 30~40
DEG C, atomizing pressure 0.16MPa, add medicine under fluidized state, after the completion of medicine-feeding, fluidized drying 15min.
(3) fluidized bed coating-protection film layer：Pure water 4100g is weighed by formula, lower add under stirring is stirred and adds into hydroxypropyl
Methylcellulose (HPMC) 200g, stirs dissolved clarification, and the protective layer membrane material solution that concentration is 5% is made, and adds talcum powder 50g, at a high speed
Emulsifying homogeneous 10 minutes, film layer coating solution must be protected by crossing 60 mesh sieves.Fluidized bed coating parameter is set：Fan delivery 180m3h-
1, feed flow revolution speed 15rmin-1, temperature of charge control are prevented under 25~35 DEG C, atomizing pressure 0.3MPa, fluidized state
Cuticular layer is coated.
(4) dry afterwards：After the completion of coating, coating micro-pill is in 30~40 DEG C of fluidized drying 30min.
The formula of embodiment 22
| Tolvaptan | 150mg |
| Sucrose blank capsule core | 4000g |
| 0.1% citron acid solution | 300ml |
| Povidone (PVP) | 8g |
| Acrylic resin | 200g |
| Water | 5000g |
Preparation method：
(1) preparation of drug solns on：Tolvaptan 200mg is weighed by formula, adds 0.1% citron acid solution 300mL dissolvings, so
It is dissolved in afterwards in the aqueous solution for including povidone (PVP) 8g and is configured to drug solns on 1500g.
(2) medicine is sprayed at fluid bed bottom：Sucrose blank capsule core 4000g is placed in fluid bed, starts fluid bed, fluidisation is set
Bed medicine-feeding parameter:Fan delivery 150m3h-1, feed flow revolution speed 5rmin-1, temperature of charge control are in 30~40 DEG C, atomization
Pressure 0.16MPa, adds medicine under fluidized state, after the completion of medicine-feeding, fluidized drying 15min.
(3) fluidized bed coating-protection film layer：Pure water about 3600g is weighed by formula, is added under stirring into acrylic resin
200g, stirs dissolved clarification, and the protective layer membrane material solution that concentration is 5% is made, and talcum powder 50g, high-speed emulsifying homogeneous are added under stirring
10 minutes, film layer coating solution must be protected by crossing 60 mesh sieves.Fluidized bed coating parameter is set：Fan delivery 180m3h-1, solution feed pump
Rotating speed 15rmin-1, temperature of charge control carry out protection film layer bag under 25~35 DEG C, atomizing pressure 0.3MPa, fluidized state
Clothing.(4) dry afterwards：After the completion of coating, coating micro-pill is in 30~40 DEG C of fluidized drying 30min.
The formula of embodiment 33
| Tolvaptan | 180mg |
| Sucrose blank capsule core | 4000g |
| 0.6% hydrochloric acid solution | 700ml |
| Syrup | 70g |
| Acrylic resin | 200g |
| Water | 4500g |
Preparation method：
(1) preparation of drug solns on：Tolvaptan 300mg is weighed by formula, adds 0.6% hydrochloric acid solution 700mL dissolvings, then
It is dissolved in the aqueous solution for including syrup 70g and is configured to drug solns on 1500g.
(2) medicine is sprayed at fluid bed bottom：Sucrose blank capsule core 4000g is placed in fluid bed, starts fluid bed, fluidisation is set
Bed medicine-feeding parameter:Fan delivery 150m3h-1, feed flow revolution speed 5rmin-1, temperature of charge control are in 30~40 DEG C, atomization
Pressure 0.16MPa, adds medicine under fluidized state, after the completion of medicine-feeding, fluidized drying 15min.
(3) fluidized bed coating-protection film layer：Pure water about 3000g is weighed by formula, is added under stirring into acrylic resin
200g, stirs dissolved clarification, and concentration is made as 5% protective layer membrane material solution, addition talcum powder 60g, high-speed emulsifying homogeneous 10 minutes,
Film layer coating solution must be protected by crossing 60 mesh sieves.Fluidized bed coating parameter is set：Fan delivery 180m3h-1, feed flow revolution speed
15rmin-1, temperature of charge control carry out protection film layer coating under 25~35 DEG C, atomizing pressure 0.3MPa, fluidized state.
(4) dry afterwards：After the completion of coating, coating micro-pill is in 30~40 DEG C of fluidized drying 30min.
The formula of embodiment 44
| Tolvaptan | 10mg |
| Sucrose blank capsule core | 400g |
| 6% ascorbic acid solution | 100ml |
| Starch slurry | 0.8g |
| HPMC | 20g |
| Water | 500g |
Preparation method：
(1) preparation of drug solns on：Tolvaptan 10mg is weighed by formula, adds 6% ascorbic acid solution 100mL dissolvings, so
It is dissolved in afterwards in the aqueous solution for including starch slurry 0.8g and is configured to drug solns on 150g.
(2) medicine is sprayed at fluid bed bottom：Sucrose blank capsule core 400g is placed in fluid bed, starts fluid bed, fluidisation is set
Bed medicine-feeding parameter:Fan delivery 150m3h-1, feed flow revolution speed 2rmin-1, temperature of charge control are in 30~40 DEG C, atomization
Pressure 0.16MPa, adds medicine under fluidized state, after the completion of medicine-feeding, fluidized drying 15min.
(3) fluidized bed coating-protection film layer：Pure water about 350g is weighed by formula, stirs lower addition HPMC 20g, stirring is molten
Clearly, the protective layer membrane material solution that concentration is 5% is made, adds talcum powder 6g, high-speed emulsifying homogeneous 10 minutes, crossing 60 mesh sieves must prevent
Cuticular layer coating solution.Fluidized bed coating parameter is set：Fan delivery 180m3h-1, feed flow revolution speed 5rmin-1, material temperature
Degree control carries out protection film layer coating under 25~35 DEG C, atomizing pressure 0.3MPa, fluidized state.
(4) dry afterwards：After the completion of coating, coating micro-pill is in 30~40 DEG C of fluidized drying 30min.
The formula of embodiment 55
| Tolvaptan | 15mg |
| Sucrose blank capsule core | 4000g |
| 0.1% citric acid soln | 200ml |
| Carmethose | 70g |
| HPMC | 200g |
| Water | 5000g |
Preparation method：
(1) preparation of drug solns on：Tolvaptan 20mg is weighed by formula, adds 0.1% citric acid soln 200mL dissolvings, so
It is dissolved in afterwards in the aqueous solution for including carmethose 70g and is configured to drug solns on 1500g.
(2) medicine is sprayed at fluid bed bottom：Sucrose blank capsule core 4000g is placed in fluid bed, starts fluid bed, fluidisation is set
Bed medicine-feeding parameter:Fan delivery 150m3h-1, feed flow revolution speed 5rmin-1, temperature of charge control are in 30~40 DEG C, atomization
Pressure 0.16MPa, adds medicine under fluidized state, after the completion of medicine-feeding, fluidized drying 15min.
(3) fluidized bed coating-protection film layer：Pure water about 3500g is weighed by formula, stirs lower addition HPMC 200g, stirring
Dissolved clarification, is made the protective layer membrane material solution that concentration is 5%, adds talcum powder 20g, high-speed emulsifying homogeneous 10 minutes, crosses 60 mesh sieves
Film layer coating solution must be protected.Fluidized bed coating parameter is set：Fan delivery 180m3h-1, feed flow revolution speed 12rmin-1,
Temperature of charge control carries out protection film layer coating under 25~35 DEG C, atomizing pressure 0.3MPa, fluidized state.
(4) dry afterwards：After the completion of coating, coating micro-pill is in 30~40 DEG C of fluidized drying 30min.
Claims (10)
- A kind of 1. tolvaptan fast release micropill preparation, it is characterised in that the fast release micropill preparation administering mode for take orally to Medicine, using blank capsule core as carrier, the tolvaptan aqueous solution containing cosolvent and adhesive is upper drug solns, the tolvaptan Dosage, according to weight ratio, tolvaptan dosage is the 0.0025~0.3% of the capsule core；The oral dose of tolvaptan is not high In 40 micrograms.
- 2. tolvaptan fast release micropill preparation as claimed in claim 1, it is characterised in that the blank capsule core is sucrose ball Core or microcrystalline cellulose capsule core；One or more of the cosolvent in citric acid, acetic acid, hydrochloric acid, ascorbic acid are pressed According to weight ratio, cosolvent dosage is the 20~300% of tolvaptan.
- 3. tolvaptan fast release micropill preparation as claimed in claim 1, it is characterised in that the adhesive is selected from hydroxypropyl first One kind or more in cellulose, povidone, syrup, starch slurry, carmethose, gelatin, Arabic gum, methylcellulose Kind, according to weight ratio, binder dosage is the 0.18~1.68% of blank capsule core.
- 4. any one tolvaptan fast release micropill preparation as described in claims 1 to 3, it is characterised in that further include protective layer Membrane material；One or more of the protective layer membrane material in acrylic resin, hydroxypropyl methylcellulose；According to weight ratio, prevent The dosage of sheath membrane material is the 1.0~5.0% of blank capsule core.
- 5. any one tolvaptan fast release micropill preparation as described in Claims 1 to 4, it is characterised in that the quick-release is micro- Ball be loaded on capsule or addition proper auxiliary materials after be pressed into tablet after be administered orally.
- 6. a kind of preparation method of tolvaptan fast release micropill preparation, it is characterised in that using blank capsule core as carrier, with containing hydrotropy The tolvaptan aqueous solution of agent and adhesive is upper drug solns, and spraying prescription method using fluid bed bottom prepares load medicine pellet, adds Protective layer membrane material solution obtains tolvaptan fast release micropill preparation through fluidized bed coating.
- 7. a kind of preparation method of tolvaptan fast release micropill preparation, including：Step 1：The preparation of upper drug solns；Step 2：Spray medicine in fluid bed bottom；Step 3：Fluidized bed coating-protection film layer；Step 4：After dry.
- 8. preparation method as claimed in claim 7, it is characterised in that the step 1 be specially by formula weigh support cut down it is general It is smooth, the citron acid solution dissolving of formula ratio is added, it is molten to be configured to quantitative medicine-feeding in the aqueous solution for being then dissolved in including adhesive Liquid.
- 9. preparation method as claimed in claim 7, it is characterised in that the step 2 is specially by the blank capsule core of formula ratio It is placed in fluid bed, starts fluid bed, the upper drug solns prepared into fluid bed in quantitative input step one, the input medicine-feeding Fluid bed medicine-feeding parameter, including 150~180m3h-1 of fan delivery, solution feed pump is set to turn by the process conditions of optimization during solution 2~7rmin-1 of speed, 25~40 DEG C of temperature of charge, atomizing pressure 0.16MPa.
- 10. preparation method as claimed in claim 7, it is characterised in that the step 3 is specially to prepare 5% by formula ratio to prevent Sheath membrane material solution, fluidized bed coating parameter are arranged to 150~180m3h-1 of fan delivery, 5~15rmin- of feed flow revolution speed 1, temperature of charge control is at 25~30 DEG C, atomizing pressure 0.3MPa；The step 4 is specially after the completion of being coated, to adjust fluid bed Parameter, coating micro-pill is in 30~40 DEG C of 15~45min of fluidized drying.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711272804.7A CN108014098A (en) | 2017-12-06 | 2017-12-06 | A kind of tolvaptan fast release micropill preparation, preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711272804.7A CN108014098A (en) | 2017-12-06 | 2017-12-06 | A kind of tolvaptan fast release micropill preparation, preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108014098A true CN108014098A (en) | 2018-05-11 |
Family
ID=62078477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711272804.7A Pending CN108014098A (en) | 2017-12-06 | 2017-12-06 | A kind of tolvaptan fast release micropill preparation, preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108014098A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021102572A (en) * | 2019-12-25 | 2021-07-15 | ニプロ株式会社 | Tolvaptan formulation |
| WO2023128903A1 (en) * | 2021-12-30 | 2023-07-06 | Santa Farma Ilac Sanayii A.S. | Improved manufacturing method for formulations comprising amorphous tolvaptan |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102114001A (en) * | 2009-12-30 | 2011-07-06 | 北京德众万全医药科技有限公司 | Orally administered solid preparation containing tolvaptan |
| CN106063780A (en) * | 2016-06-28 | 2016-11-02 | 国家***第三海洋研究所 | A kind of tetradoxin fast release micropill preparation, preparation method and applications |
-
2017
- 2017-12-06 CN CN201711272804.7A patent/CN108014098A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102114001A (en) * | 2009-12-30 | 2011-07-06 | 北京德众万全医药科技有限公司 | Orally administered solid preparation containing tolvaptan |
| CN106063780A (en) * | 2016-06-28 | 2016-11-02 | 国家***第三海洋研究所 | A kind of tetradoxin fast release micropill preparation, preparation method and applications |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021102572A (en) * | 2019-12-25 | 2021-07-15 | ニプロ株式会社 | Tolvaptan formulation |
| JP7352175B2 (en) | 2019-12-25 | 2023-09-28 | ニプロ株式会社 | tolvaptan formulation |
| WO2023128903A1 (en) * | 2021-12-30 | 2023-07-06 | Santa Farma Ilac Sanayii A.S. | Improved manufacturing method for formulations comprising amorphous tolvaptan |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5985322A (en) | Method for the treatment of CNS disorders | |
| CN106063780B (en) | A kind of tetradoxin fast release micropill preparation, preparation method and applications | |
| CN104013592B (en) | Memantine sustained release pill and preparation method thereof | |
| WO2018086498A1 (en) | Pharmaceutical composition and application thereof | |
| EP0804172A1 (en) | Controlled release potassium dosage form | |
| EP3813831B1 (en) | Extended release compositions comprising trihexyphenidyl | |
| CN107049981A (en) | A kind of quick-release Amisulpride pharmaceutical composition and preparation method thereof | |
| CN108014098A (en) | A kind of tolvaptan fast release micropill preparation, preparation method | |
| CN103520129B (en) | Montelukast sodium pulse release preparation | |
| CN106727420A (en) | A kind of net fast release micropill preparations of En Gelie, preparation method | |
| CN107982241B (en) | Potassium sodium dehydroandroan drographolide succinate enteric preparation and preparation method thereof | |
| CN106606502A (en) | Doxylamine succinate-pyridoxine hydrochloride enteric-coated tablet pharmaceutical composition and preparation method thereof | |
| CN106727395A (en) | A kind of Apremilast fast release micropill preparation, preparation method | |
| CN106619567A (en) | Trelagliptin succinate rapid-release pellet preparation and preparation method thereof | |
| CN107982268A (en) | A kind of tolvaptan preparation and its application | |
| CN108553435A (en) | A kind of Valsartan piece and preparation method thereof | |
| CN108057029A (en) | A kind of Zaltoprofen fast release micropill preparation, preparation method | |
| CN109646417A (en) | A kind of Trimetazidine sustained release tablets and preparation method thereof | |
| CN108096219A (en) | A kind of ranolazine fast release micropill preparation, preparation method | |
| CN106667961A (en) | Minodronic acid quick-release pellet preparation and preparation method | |
| CN108853017B (en) | Prescription and preparation process of estriol nano oral preparation | |
| CN106860424A (en) | A kind of Tadalafei fast release micropill preparation, preparation method | |
| CN106860423A (en) | A kind of Desloratadine fast release micropill preparation, preparation method | |
| CN106619555A (en) | Diacerein quick-release pellet preparation and preparation method | |
| CN107982243A (en) | A kind of nebivolol hydrochloric acid fast release micropill preparation, preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180511 |
|
| WD01 | Invention patent application deemed withdrawn after publication |